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Abstract
Development of high throughput analytical methods has given physicians the potential access to extensive and patient-
specific data sets, such as gene sequences, gene expression profiles or metabolite footprints. This opens for a new approach
in health care, which is both personalized and based on system-level analysis. Genome-scale metabolic networks provide a
mechanistic description of the relationships between different genes, which is valuable for the analysis and interpretation of
large experimental data-sets. Here we describe the generation of genome-scale active metabolic networks for 69 different
cell types and 16 cancer types using the INIT (Integrative Network Inference for Tissues) algorithm. The INIT algorithm uses
cell type specific information about protein abundances contained in the Human Proteome Atlas as the main source of
evidence. The generated models constitute the first step towards establishing a Human Metabolic Atlas, which will be a
comprehensive description (accessible online) of the metabolism of different human cell types, and will allow for tissue-level
and organism-level simulations in order to achieve a better understanding of complex diseases. A comparative analysis
between the active metabolic networks of cancer types and healthy cell types allowed for identification of cancer-specific
metabolic features that constitute generic potential drug targets for cancer treatment.
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Introduction
Abnormal metabolic states are at the origin of many diseases
such as diabetes, hypertension, hearth diseases and cancer, which
can be seen in many aspects as a metabolic disease. Cancer and
coronary diseases are the two main causes of death in the
developed countries. It is expected that by 2030 close to 200
million persons (33% of the total population) will be obese in the
EU alone, and many of these will have one or more of the
following co-morbidities: diabetes, hypertension, heart disease and
increased risk of cancer, and the direct (medical treatment) and
indirect (inability to work) costs are estimated to amount to more
than J100 billion per year [1,2]. The molecular mechanisms
involved in these kinds of diseases are complex and in many cases
different underlying molecular causes lead to the same disease
phenotypes. A good understanding of human metabolism in
different human cell types, whole tissues, and the interactions
between them is therefore a necessary step towards efficient
diagnosis and treatment of these diseases. Metabolism is, however,
complex and involves a very large number of individual reactions
that are highly interconnected through the sharing of common
metabolites [3]. Understanding the function of metabolism
therefore requires analysis of the complete metabolic network,
and this is best done through the use of so-called genome-scale
metabolic models (GEMs) [4,5,6].
There are three generic genome-scale human metabolic
networks currently available, namely Recon1 [7], the Edinburgh
Human Metabolic Network (EHMN) [8] and HumanCyc [9].
These reconstructions, however, are not tissue specific, which
prevents their applicability to the study of particular human cell
types or diseases. Tissue specific transcription profiles were used to
generate tissue specific models for 10 different human tissues [10],
which are subsets of Recon1, but these networks were not
sufficiently flexible to explore the metabolic states of the tissues
under various genetic and physiological conditions [11]. The same
group later proposed a different algorithm that combines
transcriptomic and proteomic data to generate a more flexible
liver specific metabolic model [11], also using Recon1 as a
template. Besides the mentioned automatically generated models,
an extensive effort led to the publication of a manually
reconstructed and annotated liver specific metabolic model
referred as HepatoNet1 [12]. Models have also been developed
for kidney [13], brain [14], erythrocytes [15] and alveolar
macrophages [16]. Computational methods used to construct cell
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type specific metabolic models aim to integrate the evidence about
the presence or absence of metabolic enzymes in a particular cell
type, while at the same time maintaining a well-connected network
(e.g. metabolites consumed in one reaction should be able to be
produced in another reaction or to be taken up from the cell
environment). Transcriptome data are often noisy and differences
in mRNA expression are not absolute but relative to a reference
condition, and in most cases do not correlate well with enzyme
levels [17]. In the frame of the Human Protein Atlas (HPA)
[18,19,20] cell type specific high quality proteomic data are being
generated based on specific antibodies, and this represents an
essential source for protein evidence in different human cell types.
Here we present a pipeline for automatic identification of
expressed cell type specific genome-scale metabolic networks
(Figure 1). A key element of the pipeline is the INIT (Integrative
Network Inference for Tissues) algorithm (Figure 2), which relies
on the HPA as the main evidence source for assessing the presence
or absence of metabolic enzymes in each of the human cell types
that are present in the HPA. Tissue specific gene expression [21]
was used as an extra source of evidence in INIT. Metabolomic
data from the Human Metabolome Database (HMDB) [22] are
also used as constraints in such a way that if a metabolite has been
found in a particular tissue the resulting network should be able to
produce this metabolite from simple precursors. More details can
be found in the description of the method.
The output of our analysis is a cell type specific metabolic
network for each of the cell types profiled in the HPA. As we are
using HPA and gene expression data our networks do not
represent the complete metabolic network that may be expressed
in each cell type, but solely the part of the metabolic network that
is expressed and hence the part of the network that is likely to be
active. In order to provide a reliable and up to date genome-scale
model template for our tissue/cell type specific metabolic
networks, we first constructed the Human Metabolic Reaction
(HMR) database containing the elements of previously published
generic genome-scale human metabolic models [7,8,9] as well as
the KEGG [23] database. This HMR database, which is
publically available at www.metabolicatlas.com, will be periodi-
cally updated as new reactions are added to KEGG or MetaCyc or
expression profiles for more proteins become available in HPA or
other databases.
In order to evaluate the capability of our pipeline to generate
reliable tissue specific metabolic networks, the metabolic model
generated for hepatocytes was compared to HepatoNet1 [12],
which is an extensively manually curated and annotated model of
high quality. The availability of active metabolic networks
corresponding to a broad set of healthy human cell types and
cancers allows for a comparative analysis between cancer and
healthy cell types in order to identify cancer specific metabolic
features that constitute potential drug targets.
Author Summary
Many serious diseases have a strong metabolic compo-
nent. The abnormal metabolic states of diseased cells
could therefore be targets for treatment. However,
metabolism is a highly complex and interconnected
system in which thousands of metabolic reactions occur
simultaneously in any given cell type. In order to
understand how metabolism of a diseased cell differs
from its healthy counterpart we must therefore study the
system as a whole. We have developed an algorithm that
integrates several types of data in order to generate active
metabolic networks; catalogues of the metabolic reactions
that are likely to be active in a given cell type. We applied
this algorithm to data for 69 healthy cell types and 16
cancer cell types. These metabolic networks can form the
basis for simulation of metabolic interactions between
organs or as scaffolds for interpretation of high-through-
put data. We used these networks to perform an analysis
between cancer and healthy cell types in order to identify
cancer specific metabolic features that constitute potential
drug targets. Several of the resulting targets were already
known and used clinically, but we also found high-ranking
reactions and metabolites which have not yet been
investigated as drug targets.
Figure 1. General pipeline used in the reconstruction of cell specific genome-scale metabolic networks. Biological information at the
genome, transcriptome, proteome and metabolome levels contained in publicly available databases and generic human GEMs (Recon1, EHMN,
HumanCyc) is integrated to form a generic human metabolic network, which is processed in order to obtain the connected iHuman1512 network.
Subsequently, the cell type specific evidence is used to generate cell type specific subnetworks using the INIT algorithm.
doi:10.1371/journal.pcbi.1002518.g001
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Results/Discussion
Database construction
The existing methods for the inference of tissue specific active
metabolic networks have only used Recon1 as a scaffold. In order
to integrate other sources of information we constructed the
Human Metabolic Reaction database (HMR), containing the two
existing genome-scale metabolic models, Recon1 and EHMN, as
well as incorporating information from HumanCyc and KEGG.
The HMR database has a hierarchical structure in which the
genes are at the top and are linked to information about their
tissue specific expression profiles reported by Su et al [21] via
BioGPS [24]. Each gene is linked to its different splicing variants
and those to their corresponding proteins. Each protein is linked to
its tissue specific abundances in the HPA database [18] and to the
reactions they catalyze. The reactions are linked to metabolites
that themselves are linked to their tissue specific information
collected from the HMDB [22]. The HMR database will be
regularly updated with new reactions contained in future genome-
scale human metabolic reconstructions, as well as with new
evidence included in future versions of the HPA, HMDB and
newly published specific transcriptome data. Details regarding the
construction and curation of the HMR database are available in
the Methods section. The INIT algorithm requires a connected
template human metabolic model as input, and this template
model was generated from HMR. The template model contains
4,137 metabolites (3,397 unique) and 5,535 reactions (4,144
unique), which are associated to 1,512 metabolic genes. This
template model is referred to as iHuman1512.
Generation of 69 tissue specific and 16 cancer type
specific genome-scale active metabolic networks
Using the INIT algorithm (see supplementary material for a
detailed description), genome-scale active networks for 69 different
cell types and 16 cancers were automatically generated. The
resulting active metabolic networks are provided in SBML [25]
format and are available at www.metabolicatlas.com.
The tissue specific models generated were compared with the
BRENDA [26] collection of detected enzymes in various tissues. A
hypergeometric test was carried out using the R statistical
software. The reported p-values are the probabilities of obtaining
an overlap higher than the observed with a random set of
metabolic genes of the same size as the corresponding BRENDA
entry. As it is shown in Table S1, all the comparisons between the
models generated by our algorithm and BRENDA showed
overlaps with p-values lower than 5e-4. Our computational liver
model (iHepatocyte1154) shows a p-value of 1e-200, which is similar
to the value obtained by comparing the manually reconstructed
HepatoNet1 to BRENDA. 55% of the genes in iHepatocyte1154 are
also in BRENDA, while only 43% of the genes in HepatoNet1 are
in BRENDA. The comparatively high p-values are for tissues for
which there are very few annotated enzymes in BRENDA.
In order to validate the output of our algorithm, our
automatically generated hepatocyte model was compared with
HepatoNet1 [12], a manually curated and functional model of
hepatocyte metabolism. The comparison was carried out at the
gene level to avoid ambiguous decisions about reaction similarity.
The overlap between the lists of genes included in each of the
Figure 2. Illustration of the principles of the INIT algorithm. The hierarchical structure of GEMs is characterized by its gene-transcript-protein-
reaction (GTPR) associations. In GEMs, each metabolic reaction is associated to one or more enzymes, which in turn are associated to transcripts and
genes. Depending on the evidence for presence/absence of a given enzyme/gene in a cell type, a score can be calculated for the reaction(s) catalyzed
by that enzyme. The HPA evidence scores are illustrated as red, light, medium and dark green representing negative, weak, moderate and strong
evidence, respectively. The transcriptome evidence scores (GeneX), which are illustrated as red, light, medium, and dark blue representing low,
medium and high expression, respectively. No evidence is present as white object. For some metabolites (yellow filled circle), metabolomic data are
available to prove that they are present in the considered cell type. The aim of the algorithm is to find a sub-network in which the involved genes/
proteins have strong evidence supporting their presence in the cell type under consideration. This is done by maximizing the sum of evidence scores.
All the included reactions should be able to carry a flux and all the metabolites observed experimentally should be synthesized from precursors that
the cell is known to take up. The bold lines represent the resulting network after optimization.
doi:10.1371/journal.pcbi.1002518.g002
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models is showed in Figure 3. Our hepatocyte model (iHepato-
cyte1154) contains 1,154 genes, of which 452 are also included in
HepatoNet1 and 702 are absent. The evidence for the expression
and translation of the 702 absent genes is as good as the evidence
for the 452 genes that are in both networks, and we are therefore
confident that the presence of most of the 702 extra genes has been
correctly inferred by our algorithm. The HepatoNet1 network
contains 261 genes not included in iHepatocyte1154, of which 156
were absent from our initial connected human network. Our
algorithm could therefore not have assigned these genes to the
hepatocyte sub-network and their existence reveals just a
limitation of the data that were used as an input and not a
limitation of our algorithm. 80 of these genes were not in HMR
(see Table S2), but closer examination revealed that the majority
(62 genes) of these genes corresponded to reactions that were
actually present in HMR, but with different or absent gene
associations. 13 out of the 18 remaining genes encode for
transporters to the sinusoidal space; a type of blood vessels in
the liver and therefore not a part of hepatocytes. The other 76
genes that were absent from iHuman1512, and their corresponding
reactions, were removed because of being unbalanced, uncon-
nected or otherwise problematic (see Table S3). 105 genes
included in HepatoNet1, and present in iHuman1512, were not
assigned by our algorithm to the hepatocyte-specific network.
These genes correspond to 237 reactions, 132 of them still exist in
iHepatocyte1154 associated to different isoenzymes. The experi-
mental evidences for the presence of these 105 genes (see Table S4)
in the hepatocytes is mostly weak or negative, even slightly worse
than the evidence for the 253 genes that were both rejected by our
algorithm and absent in HepatoNet1, and we are therefore
confident that these 105 genes were correctly rejected. This shows
the importance of using cell type specific data when reconstructing
GEMs, as enzyme isoforms can be differentially expressed in
different cell types. Based on the above we can conclude that the
Figure 3. Gene content comparison between our hepatocyte model and HepatoNet1. The Venn diagram shows the overlap in terms of
included genes between three models. The blue, green and red squares represent iHuman1512, our hepatocyte model iHepatocyte1154 and
HepatoNet1, respectively. The distribution of evidence scores of each section of the Venn diagram is plotted. The HPA evidence scores are illustrated
as red, light, medium and dark green represent negative, weak moderate and strong expression, respectively. The transcriptome evidence scores
(GeneX) are illustrated as red, light, medium and dark blue representing low, medium and high expression, respectively. No evidence (NE) is
illustrated as grey color.
doi:10.1371/journal.pcbi.1002518.g003
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mismatches between our hepatocyte-specific metabolic network
and HepatoNet1 are accompanied by experimental evidence in
favour of the choices made by our algorithm.
Finally we clustered the 69 plus 16 metabolic networks
according to their similarity in terms of shared metabolic genes
using unsupervised hierarchical clustering with average linkage
and multiscale bootstrap resampling [27] (10,000 repetitions)
implemented in the R statistical software (see Figure S1). The
clustering shows, as it could be expected, local grouping of closely
related cell types on the basis of cell anatomy (e.g. spleen in red
pulp and white pulp cluster together). Interestingly, the cancers are
separated into three different clusters, one containing liver,
colorectal, breast and endometrial cancer, another minor cluster
including cervical and head cancer and a third one containing the
remaining ten cancers. It is also of interest to note that only 189
reactions (4.1% of the total number of reactions) are unique to a
single cell or cancer type, while there is a larger core-set of 501
reactions (11.0% of total number of reactions) that are in common
to all cells. Figure S2 shows the enrichment of some important
metabolic pathways in the models.
Identification of cancer specific metabolic features
Since the Warburg effect was observed at the beginning of the
20th century, it is known that cancer cells show characteristic
metabolic features that make them different from healthy cells
[28]. This supposed metabolic similarity between cancer cells
justified the development of a generic cancer genome-scale
metabolic model which was used to identify potential drug targets
against cancer proliferation [29]. Here we have inferred active
metabolic networks for 16 different cancer types, which can be
compared with the 24 healthy cell types that they come from (there
are several healthy cell types for some of the tissues associated to
the cancers) in order to identify metabolic features that are
characteristic of cancer. A hypergeometric test was used to identify
genes and reactions that tend to be present in most of the cancer
specific active metabolic networks and absent in most of the
original healthy cell types (see Tables S5 and S6). The p-values
obtained from the hypergeometric test were used to identify
Reporter Metabolites [30] that are significantly more involved in
the metabolism of cancer cells (see Table S7). The sets of genes,
reactions and metabolites showing enrichment in the cancer active
metabolic networks with p-values lower than 1e-4 are listed in the
supplementary material. These lists of genes, reactions and
metabolites are cancer specific features that are likely to be
playing a specific role in proliferation of cancer cells and could be
potential drug targets. Our comparative analysis between two sets
of active metabolic networks can be seen as a high throughput
hypothesis generation method. These hypotheses are not based on
mere correlations between cancer and the presence of a particular
protein, but being based on the underlying metabolic network
structure, and hereby our analysis provides a mechanistic
interpretation about the possible role of each identified feature
on the proliferation of cancer.
One of the most significant results from the Reporter
Metabolites analysis is a much more pronounced metabolism of
polyamines (PAs) such as spermidine, spermine, and putrescine in
cancer cells. PAs play a variety of roles, of which several are
related to oxidative stress prevention and suppression of necrosis
[31]. PAs have long been known to be of particular importance for
rapidly proliferating cells, and as such its transport and synthesis
have been thoroughly investigated as anti-cancer drug targets [32].
Inhibition of single enzymes in the PA synthesis pathway has
proved disappointing, due to extensive regulation of the system
and use of exogenous PAs by the cancer cells. Second generation
drugs instead work by targeting the transport system, by structural
homology to the PAs themselves, or by linking other aneoplastic
drugs to the PAs [33].
Another high-ranking target is the isoprenoid biosynthesis
pathway, in particular the intermediate geranylgeranyl diphos-
phate. This metabolite has been shown to promote oncogenic
events due to its role in prenylation of important cancer proteins
such as Ras and Rho GTPases [34]. Several drugs have therefore
been developed to target the prenylation process [35] or the
biosynthesis of geranylgeranyl diphosphate [36].
A third prominent group among the Reporter Metabolites is
prostaglandins and leukotrienes together with the intermediate
HPETE. These autocrine compounds are synthesized from
arachidonic acid and are elevated in connection with inflamma-
tion. They have been shown to aid in cancer progression by
promoting metastasis and by influencing the immune system [37].
Of particular interest is prostaglandin E2, where both the synthesis
and degradation have been investigated as promising targets for
drug development [38].
The fact that so many of the identified targets correspond to
well known and used drug targets, indicates that the method is able
to generate biologically relevant hypotheses. Of particular interest
are therefore the Reporter Metabolites that are currently not
targeted in cancer treatment. Among the top-scoring Reporter
Metabolites we identified biliverdin and bilirubin (Figure 4).
Biliverdin reductase and the reactions catalyzed by this enzyme
also appear among the genes and reaction most enriched in the
cancer networks. Biliverdin reductase is known to be a major
physiologic cytoprotectant against oxidative stress [39]. Cancer
cells are known to be exposed to high oxidative stress resulting
from the hydrogen peroxide generated during the oxidation of
polyamines and other products of amino acid breakdown taking
place in the peroxisome. Bilirubin is oxidized to biliverdin by
hydrogen peroxide and subsequently reduced back to bilirubin by
biliverdin reductase. This mechanism has been proven to be a
major relief system for oxidative stress and could be considered a
potential target against cancer proliferation. One of the hydrogen
peroxide generating reactions taking place in the peroxisomes is
the transformation of aminoacetone, which is an intermediate in
the degradation of glycine, into methylglyoxal. Another source of
methylglyoxal in cancer cells is from gluconeogenesis [40].
Methylglyoxal is known to be a toxic compound [41] that has
been proven to induce apoptosis in some cancer cell lines [42].
Methylglyoxal also appeared among our top scoring reporter
metabolites and both the gene coding for lactoylglutathione lyase
(an enzyme that transforms methylglyoxal and glutathione into
lactoylglutathione) and its associated reactions appear among the
most enriched genes and reactions in the cancer active metabolic
networks. Lactoylglutathione is further transformed into glutathi-
one and lactic acid by the enzyme lactoylglutathione hydrolase
(which also shows a significant enrichment in cancer metabolic
networks with a p-value of 2e-3). Lactic acid is a well known
metabolite produced by cancer cells. The mentioned two enzymes
seem to be playing a relevant role in relieving the toxicity
generated by methylglyoxal and could be potential drug targets
against cancer proliferation. Targeting these enzymes would have
the same effect on cancer cells as using methylglyoxal as a drug,
but the advantage is that there would be no toxicity effects of
methylglyoxal on healthy tissues.
Conclusions and perspectives
We here present a method that is able to integrate different
sources of biological evidence to generate high quality cell type
specific metabolic networks. We used this method to generate
Reconstruction of Metabolic Networks Using INIT
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genome-scale metabolic networks for 69 different human cell types
and 16 cancer types, and this is the first step towards the
establishment of a Human Metabolic Atlas, which may become a
central portal for further advancing human metabolic models with
the capability of performing tissue-level and organism-level
metabolic simulations, allowing for a better understanding of
complex diseases. The Human Metabolic Atlas and will be made
publicly accessible for the medical and scientific community and
may hereby become a valuable resource in the development of
personalized medicine based on system-level analysis. An example
of system-level analysis is the identification of cancer specific
metabolic features that we have performed by comparing the
networks generated using the INIT algorithm.
Methods
Database construction
In order to have an unambiguous characterization of metab-
olites and reactions, KEGG and InChI identifiers were used for
standardization. Metabolites lacking identifiers to external data-
bases were left out of the HMR database together with their
corresponding reactions. The metabolite identifiers were used to
infer if two reactions coming from different sources were the same.
Each reaction was assigned to one or several of the eight
compartments included in the HMR database: nucleus, cytosol,
endoplasmatic reticulum, Golgi apparatus, peroxisomes, lyso-
somes, mitochondria and extracellular. In cases where the sub-
cellular localization was absent from the template models it was
inferred from immunohistochemical staining in the HPA. For
enzymes that were not in the HPA, Swiss-Prot and GO were used
to infer localization (see Table S8 for database versions). After
removing the compounds that lack identifiers, the database
contained 9,922 reactions, 2,366 genes, and 9,581 metabolites
for the eight different compartments (3,547 unique metabolites
and 6,319 unique reactions when compartmentalization is not
considered). There are 338 of these metabolites which, even if they
have KEGG identifiers, are generic compounds such as ‘‘Lipid’’ or
‘‘2-oxoacid’’. Such compounds can lead to reactions that are
elementally unbalanced. These problematic metabolites were
removed, together with the 418 reactions in which they were
involved after a detailed manual curation process. 38 reactions
with wrong or unbalanced stoichiometries were also substituted by
balanced versions during the curation process. In order to avoid
problems associated with proton balancing, which arise from
undefined protonation states of many metabolites, free exchange
of protons was allowed in the models. Finally, all reactions unable
to carry flux under any circumstance were removed. The reason
for removing these unconnected reactions was that the algorithm
requires a connected model as input. After this filtering, our
template model contains 4,137 metabolites (3,397 unique) and
5,535 reactions (4,144 unique), which are associated to 1,512
metabolic genes (based on the Ensemble gene catalogue). This
template model is referred to as iHuman1512. The numbers of
genes maintained in each of the above mentioned steps are listed
in Table S9. The discrepancy between the large number of
reactions and the relatively small number of genes, which is also
seen in previously published metabolic networks, is due to the fact
that many reactions are included in the template networks based
on literature studies or for connectivity reasons. In addition, some
enzymes catalyze a large number of reactions and some enzymes
catalyze reactions in several compartments. A comparison
between iHuman1512 and some published human metabolic
networks is available in Table S10.
Algorithm for the generation of tissue-specific models
Several algorithms aiming to obtain a tissue or condition-
specific active set of metabolic reactions from a generic model
have been previously developed. The first of these algorithms was
the Gene Inactivity Moderated by Metabolism and Expression
(GIMME) algorithm [43], which uses mRNA expression data as
Figure 4. Example of a metabolic sub-network that was identified as being significantly more present in cancer tissues compared to
their corresponding healthy tissues. Aminoacetone, which is a toxic by-product of amino acid catabolism, is converted to toxic methylglyoxal in
a reaction that also result in hydrogen peroxide. The toxicity of methylglyoxal is relieved by two reaction steps involving ligation to glutathione and
resulting in lactic acid. The generated hydrogen peroxide is taken care of by the enzyme biliverdin reductase. This is an example of how network-
based analysis can lead to a more mechanistic interpretation of data.
doi:10.1371/journal.pcbi.1002518.g004
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input. Two other algorithms were developed with the specific aim
of generating human tissue specific metabolic networks. The first
of those [10],_ENREF_10 developed by Shlomi and co-workers,
used transcriptomic data as its sole input. The second one [11] was
developed by the same authors in order to obtain a functional
model for human hepatocytes and is able to integrate also
metabolomic and proteomic data.
The INIT (Integrative Network Inference for Tissues) algorithm
is formulated as a mixed integer-linear problem (MILP) and is
specially tailored to use the evidence from the HPA as input. The
problem is formulated so that all reactions in the resulting model
are able to carry flux. The stoichiometric matrix S contains the
stoichiometric coefficients for each internal metabolite in each
reaction. By multiplying the stoichiometric matrix by the vector of
reaction rates we obtain a vector of net accumulation or
consumption rates for each internal metabolite. Instead of
imposing the steady state condition for all the internal metabolites,
as it is usually done, we allow for a small positive net accumulation
rate. The net productions of metabolites will be given positive
weights in the optimization. The reason for this choice is that we
prefer to have a network able to synthesize molecules such as
NADH or NADPH, rather than only being able to use them as
cofactors. If a metabolite is present in a cell type (according to the
HMDB) a positive net production of this metabolite will be
imposed to the network in order to assure that all the reactions
necessary for its synthesis are included in the tissue specific model.
Up to this date there is not a human biomass equation available
in the literature (for example Recon1 incorporates a mouse
biomass equation). On the other hand, human cells (with the
exception of cancer cells), in contrast to microorganisms, do not
tend to proliferate or do so slowly in comparison with the rest of
their metabolic functions. This makes the biomass equation less
relevant, unless the aim is to model cancer proliferation. Also
human cells secrete into the blood a much broader spectrum of
compounds than microbial cells secrete into their environment
(which are mainly fermentation products). We therefore chose to
generate networks allowing for secretion (or accumulation) of all
their metabolites. If we had used the stricter steady state
constraint, many reactions would have been removed from the
models just because they were leading to dead end metabolites.
These end metabolites could in fact be added to biomass or just be
secreted into the blood stream, therefore we have aimed for a
more flexible approach by allowing secretion (or net accumulation)
of metabolites.
The MILP used in INIT can be specified as:
max
X
i[R
wiyiz
X
j[M
xj
 !
S~v~~b
vij jƒ1000yi
vij jz1000 1{yið Þ§e
vi§0,i[irreversible rxns
bjƒ1000xi
bjz1000 1{xið Þ§e
bj§0
xj~1, j[present
yi,xj[ 0,1f g
ð1Þ
The parameter e is an arbitrarily small positive number. The
weights of the binary variables corresponding to the reactions
account for the evidence of their presence or absence. When the
corresponding enzyme has been characterized in the HPA we
have used values of wi of 20, 15, 10 and 28 for high, medium, low
and absent proteins respectively. These scores are arbitrary and
have been chosen to quantify the evidence colour codes that
appear in the HPA. We have tested the sensitivity of the algorithm
to the variation in these weights by perturbing them by 20% up
and down and the impact on the output of the algorithm resulted
only in small changes of the resulting networks. If the evidence
comes from gene expression levels which were retrieved from
BioGPS [24] and the publicly dataset ‘‘Human Body Index –
Transcriptional Profiling’’ (GSE7307), we have used weights
calculated as follows:
wi,j~5 log
Signali,j
Averagei
 
ð2Þ
The signal of gene i in tissue j is divided by the average signal
across all the tissues. If the signal in a particular tissue is higher
than its average across all the tissues the weight will be positive, if it
is lower it will have a negative weight.
For the reactions that are related to several genes or proteins the
highest evidence score is used. If no gene is associated to a
particular reaction, or there is no proteomic or transcriptomic
evidence, a weight of 22 is used in order to avoid adding
unnecessary reactions without evidence and keep the network as
parsimonious as possible. If a reaction linked to several genes is
added to the final tissue specific network, only the genes showing a
positive evidence score are kept in the tissue specific reaction-gene
association.
The MILP problem was solved using MOSEK (www.mosek.
com) and its Matlab interface.
Supporting Information
Figure S1 Clustering of 69 predicted cell type specific
genome-scale metabolic models for normal tissues
together with 16 for cancer tissues. A dendrogram
generated by unsupervised hierarchical clustering of the models
based on predicted gene presence and absence is shown.
(PDF)
Figure S2 The relative pathway enrichment profiles,
based on KEGG pathways, for each of the models. Blue
corresponds to underrepresentation and red to overrepresentation.
Note that it is the number of enzymes present for each pathway
that underlie the comparison, not the abundances of the proteins.
(PDF)
Table S1 Evaluation of the models by comparison to
curated tissue-specific enzymes. For each model, the set of
genes is compared to the set of genes annotated as existing in the
corresponding tissue in BRENDA. The p-values are derived from
hypergeometric distribution.
(PDF)
Table S2 Investigation of the 80 genes that were present
in HepatoNet1 but missing in HMR. The 80 missing genes
were associated with 746 reactions in HepatoNet1, of which 597
metabolic and transport reactions were related to the sinusoidal
space compartment. 117 metabolic reactions existed in HMR with
different gene or no gene association and 32 (5 unique) reactions
were altogether absent in HMR. KEGG reaction identifiers or
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Transporter Classification database identifiers (TCDB) are
provided for the missing reactions.
(PDF)
Table S3 Investigation of the 76 genes that were
removed during the pre-processing steps. 76 genes which
were present in both HepatoNet1 and the HMR database were
removed in order to get a fully connected input network for the
INIT algorithm. This table summarizes which genes were
removed during each of the pre-processing steps (see Table S2
for details).
(PDF)
Table S4 Investigation of the 105 genes which are
present in HepatoNet1 but missing in iHepatocyte1154
due to the INIT algorithm. The 105 missing genes were
associated with 182 reactions in HepatoNet1, of which 5 metabolic
reactions are related to the sinusoidal space compartment. 108
metabolic reactions existed in iHepatocyte1154 with different gene
or no gene association and 69 (60 unique) reactions are absent in
iHepatocyte1154 due to INIT algorithm. KEGG reaction identifiers
are provided for the missing associated reactions to the genes.
(PDF)
Table S5 List of reactions that were significantly more
present in cancer tissues compared to their correspond-
ing normal tissues (p-value,10e-4).
(PDF)
Table S6 List of genes for which their corresponding
reactions were significantly more present in cancer
tissues compared to their corresponding normal tissues
(p-value,10e-4).
(PDF)
Table S7 List of Reporter Metabolites (p-value,10e-4).
(PDF)
Table S8 Versions of the databases used in the creation
of the Human Metabolic Reaction database (HMR).
(PDF)
Table S9 Number of the genes after each pre-process-
ing step during the generation of iHuman1512. Since the
INIT algorithm provides a connected and functional model,
reactions that are unconnected in the template model can never be
included. In order to separate between reactions that were
excluded due to connectivity reasons and those that were excluded
due to negative evidence, a number of preprocessing steps were
performed on the data in the HMR database. In the first step
reactions that contain very generic metabolites such as ‘‘lipid’’ or
‘‘alcohol’’ were removed. Reactions that were elementally
unbalanced were fixed or removed. Simulations were performed
to ensure that the network could not gain carbon, energy or redox
power in an unbalanced manner. In the second step reactions
where directionality information was lacking were removed. In the
third step reactions where one or more of the substrates could not
be synthesized through some other reaction (unconnected
reactions) were removed. Finally, in the fourth step reactions that
couldn’t carry flux when the model had access to all exchange
metabolites (as defined in the EHMN) were removed. Conse-
quently, iHuman1512, a connected human network with 5,535
reactions, associated with 1512 protein coding genes, was
generated. The number of genes associated to the remaining
reactions after each pre-processing steps are presented below.
(PDF)
Table S10 Comparison between iHuman1512 and some
other published human metabolic networks.
(PDF)
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